SlideShare a Scribd company logo
1 of 21
The Royal Marsden
1
Nursing and Service Aspects of
Extracorporeal Photopheresis
( ECP)
Janet Baker (Sister-Haem-Onc Daycare/Outpts/Apheresis)
Royal Marsden NHS Foundation Trust
EBMT NAP UK 5/10/2012
The Royal Marsden
2
Background
 Opportunity to deliver ECP at RMH
 Commercially sponsored clinical trial: ECP for 1st line
Chronic GvHD
 Provision of CellEx™ Photopheresis system
 Charity funded programme for Acute GvHD
 Development of an ECP service
The Royal Marsden
3
Discussion Points
 Clinical Governance Issues
 Management, Organisation, and Personnel
 Training and Supervision
 Premises-Space-Storage
 Key Documentation
 Quality Assurance/ Standards
 Patient Management
The Royal Marsden
4
Clinical Governance Issues
 Service Objectives / Outcome
 Service Agreements/ Maintenance
 New Equipment User Group
 Drug and Therapeutics Committee-Approval for 8-
Methoxypsoralen (Uvadex™)
 Risk Assessment
 Incident Reporting System
 Procurement
 Finance Reporting- updates to Charity Fund
The Royal Marsden
5
Management, Organisation, and Personnel
 ? Extension / Integration of Apheresis service
 Inpatient / outpatient service
 Designated leads/ Keyworkers: Nursing and Medical
 Accountability / Responsibility
 Skill mix / Experience: Apheresis + Transplant
 Resources: Nursing Staff and Time
 Institutional / Department support
The Royal Marsden
6
Training Requirements
 Technical Competency Certificate from Company Trainer –
‘water treatment’ and patient treatments
 Theoretical component- workbook
 Arranged observational visit to Nottingham -ECP
 Strasbourg- Company HQ, and clinical observational visit
 On- the – job training / learning….ongoing
 Instruction Manual
The Royal Marsden
7
Premises – Space - Storage
 CellEx™
 Location of procedure – Inpt/ Outpt/ Apheresis
 Therapeutic environment
 Service is portable
 Storage of kits
The Royal Marsden
8
Key Documentation
 Standard Operating Procedure ( SOP) for ECP
 Patient Consent Form
 Patient Information Leaflet
 Photopheresis Procedure record
 Prescription/ Proforma -Uvadex™ / Heparin
 GvHD monitoring/ assessment form
 FACT-BMT Quality of Life questionnaire
 Reporting forms for System failures/Incidents
 Maintenance and Cleaning records
The Royal Marsden
9
Quality Assurance / Standards
 SOP policy for ECP and associated policies
 JACIE accredited centre
 JACIE 5th
edn standards B7.2 acknowledge:
- “Inspectors are encountering ECP processes
during inspection-if part of therapy for GvHD-
must comply with JACIE standards-performed
according to policies for safe administration of
ECP”
 UK Photopheresis Society (UKPS) advocates ECP
accreditation in UK / Europe by external assessment
The Royal Marsden
10
Patient Management
 Patient selection / Eligibility for treatment – SOP
‘ to ECP or not to ECP?’
 Further consensus guidelines for acute GvHD needed
 Scheduling –treatment efficacy -Acute –twice weekly-8 wks
- Chronic- per trial / 2x week every 2 weeks
- logistics and practicalities
 Clinical pre-assessment criteria-blood values (Fbc, Coag,
U&es, Lfts, lipids) / Weight
 Baseline GvHD assessment and I/S medication review
The Royal Marsden
11
Patient Consent / Information
 Commitment / Compliance
 Repeat hospital visits
 Inpt/ Outpt
 Realistic aims and timeframes- not ‘quick fix’
 Support / Reassurance
 Low fat diet- ( lipids)
 UVA protection skin / eyes - dark glasses
 Contraception – (Uvadex ™)
 Good oral hydration
 Acute/ Chronic GvHD pts… different needs
The Royal Marsden
12
Side –effect profile
 Fatigue
 Hypotension / dizziness/ syncope - ECV
 Increased sensitivity to sunlight- skin / eyes
 Pain, anxiety, bruising – peripheral cannulation
 Infection- central access lines
 Bleeding/ bruising – anticoagulation
 Metallic taste in mouth , ‘sparkly’ sensation in eyes
during re-infusion
The Royal Marsden
13
Venous access - vein assessment
 Peripheral Access– Kimal needle size 16/17
- 17/18 g cannula
Return - 18/ 20 g cannula
 Central Line –Double lumen
- LTS line(long term silicone,tunnelled)
- 12 French ( 5.5 mm per lumen)
- > 3 French per lumen
- provide flow rates > 15 ml/ min
 CellEx™ - Single or Double lumen procedure
The Royal Marsden
14
Transfusion Requirements pre ECP
 Institutional Parameters
 Hct > 27 %
 Platelets > 25,ooo
 Blood results < 48 hours pre procedure
The Royal Marsden
15
Anticoagualtion
 System licensed for Heparin not Citrate
 ? Anticoagulant not anti-platelet clumping activity
 10,ooo units Heparin in 500 mls / AC ratio 10:1
 Adjust for high/ low platelet counts
 Watch for Platelet Clumping
 Assess for bleeding, bruising - haematuria
 Patient anti-coag history- INR
The Royal Marsden
16
Technical problems
 CellEx™ Alarms
 Problem solving
 Technical support - Hotline / UK trainer
 Kits - Reimbursement if problems
 Smart Cards- send for analysis
 Reporting / Documenting System and kit problems
The Royal Marsden
17
Assessment, Monitoring, Evaluation
 Efficacy v toxicity of treatment - ECP good safety
profile
 GvHD assessments - who should complete these?
 Record Clinical Outcomes - ? National ECP database
 Quality of Life information
 Financial Outcomes - Commissioners / Reimbursement
and future funding
 Evidence -based and cost- effective service
The Royal Marsden
18
Our experience so far…….
 3 AGvHD patients treated- 1 in treatment
 CGvHD Trial - 1 pt enrolled- not randomised to ECP
 ? Future after funding/ trial complete
 Challenging / time-consuming
 Great opportunity for us and our patients
 Collaboration and networking with other ECP centres
The Royal Marsden
19
Acknowledgement / Thanks
 Regina De Jesus - Joint ECP Key- worker
- Sister, Transplant Unit, RMH
 Nurses on Bud Flanagan Ambulatory Care ( BFAC)
 ECP experts, esp - Emma Luke at Nottingham
- Tracy Maher and Maggie Foster at
Rotherham
The Royal Marsden
20
Thank You for listening.
– Questions?
The Royal Marsden
21
References
 FACT-JACIE International Standards for Cellular
Therapy Product Collection, Processing, and
Administration. 5th edition. JACIE

More Related Content

What's hot

Craig N. Setti Resume (14)
Craig N. Setti Resume (14)Craig N. Setti Resume (14)
Craig N. Setti Resume (14)Craig Setti RCIS
 
InHome Hospice Support Model
InHome Hospice Support ModelInHome Hospice Support Model
InHome Hospice Support Modeltlavelle
 
Disease-Specific Care Certification for Hip and Knee Replacement Programs
Disease-Specific Care Certification for Hip and Knee Replacement ProgramsDisease-Specific Care Certification for Hip and Knee Replacement Programs
Disease-Specific Care Certification for Hip and Knee Replacement ProgramsWellbe
 
John Sweeney, Director, Healthcare Informed
John Sweeney, Director, Healthcare InformedJohn Sweeney, Director, Healthcare Informed
John Sweeney, Director, Healthcare InformedInvestnet
 
CBCC Global Presentation
CBCC Global PresentationCBCC Global Presentation
CBCC Global PresentationHarini Patel
 
Cell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCovance
 
ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...
ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...
ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...Advanced Cell Technology, Inc.
 
ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...
ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...
ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...Advanced Cell Technology, Inc.
 
The Australian Specific Annex document
The Australian Specific Annex documentThe Australian Specific Annex document
The Australian Specific Annex documentTGA Australia
 
Cell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCovance
 
Post-market RMP/ASA updates
Post-market RMP/ASA updatesPost-market RMP/ASA updates
Post-market RMP/ASA updatesTGA Australia
 
Presentation: Draft Clinical Evidence Guidelines – Medical Devices
Presentation: Draft Clinical Evidence Guidelines – Medical DevicesPresentation: Draft Clinical Evidence Guidelines – Medical Devices
Presentation: Draft Clinical Evidence Guidelines – Medical DevicesTGA Australia
 
Operating an Independent Health Facility
Operating an Independent Health FacilityOperating an Independent Health Facility
Operating an Independent Health FacilityFordly
 
How accurate urine collection = £1.2bn savings for the NHS.
How accurate urine collection = £1.2bn savings for the NHS.How accurate urine collection = £1.2bn savings for the NHS.
How accurate urine collection = £1.2bn savings for the NHS.Giovanna Forte
 
Healthcare facility Quality and Operational proposal by Mahboob ali khan MHA,...
Healthcare facility Quality and Operational proposal by Mahboob ali khan MHA,...Healthcare facility Quality and Operational proposal by Mahboob ali khan MHA,...
Healthcare facility Quality and Operational proposal by Mahboob ali khan MHA,...Healthcare consultant
 
Compliance history as a driver for reinspection frequencies
Compliance history as a driver for reinspection frequenciesCompliance history as a driver for reinspection frequencies
Compliance history as a driver for reinspection frequenciesTGA Australia
 

What's hot (20)

Craig N. Setti Resume (14)
Craig N. Setti Resume (14)Craig N. Setti Resume (14)
Craig N. Setti Resume (14)
 
InHome Hospice Support Model
InHome Hospice Support ModelInHome Hospice Support Model
InHome Hospice Support Model
 
Disease-Specific Care Certification for Hip and Knee Replacement Programs
Disease-Specific Care Certification for Hip and Knee Replacement ProgramsDisease-Specific Care Certification for Hip and Knee Replacement Programs
Disease-Specific Care Certification for Hip and Knee Replacement Programs
 
John Sweeney, Director, Healthcare Informed
John Sweeney, Director, Healthcare InformedJohn Sweeney, Director, Healthcare Informed
John Sweeney, Director, Healthcare Informed
 
CBCC Global Presentation
CBCC Global PresentationCBCC Global Presentation
CBCC Global Presentation
 
Action proposal
Action proposalAction proposal
Action proposal
 
Jci material
Jci materialJci material
Jci material
 
Cell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval Solutions
 
ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...
ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...
ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...
 
ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...
ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...
ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...
 
The Australian Specific Annex document
The Australian Specific Annex documentThe Australian Specific Annex document
The Australian Specific Annex document
 
Cell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval Solutions
 
Post-market RMP/ASA updates
Post-market RMP/ASA updatesPost-market RMP/ASA updates
Post-market RMP/ASA updates
 
Presentation: Draft Clinical Evidence Guidelines – Medical Devices
Presentation: Draft Clinical Evidence Guidelines – Medical DevicesPresentation: Draft Clinical Evidence Guidelines – Medical Devices
Presentation: Draft Clinical Evidence Guidelines – Medical Devices
 
Operating an Independent Health Facility
Operating an Independent Health FacilityOperating an Independent Health Facility
Operating an Independent Health Facility
 
How accurate urine collection = £1.2bn savings for the NHS.
How accurate urine collection = £1.2bn savings for the NHS.How accurate urine collection = £1.2bn savings for the NHS.
How accurate urine collection = £1.2bn savings for the NHS.
 
Owen Vaughan prometics crdn summit 2017
Owen Vaughan prometics crdn summit 2017Owen Vaughan prometics crdn summit 2017
Owen Vaughan prometics crdn summit 2017
 
Healthcare facility Quality and Operational proposal by Mahboob ali khan MHA,...
Healthcare facility Quality and Operational proposal by Mahboob ali khan MHA,...Healthcare facility Quality and Operational proposal by Mahboob ali khan MHA,...
Healthcare facility Quality and Operational proposal by Mahboob ali khan MHA,...
 
Compliance history as a driver for reinspection frequencies
Compliance history as a driver for reinspection frequenciesCompliance history as a driver for reinspection frequencies
Compliance history as a driver for reinspection frequencies
 
JCIA PRESENTATION
JCIA PRESENTATIONJCIA PRESENTATION
JCIA PRESENTATION
 

Similar to Nursing aspects-of-ecp

Technology in the office
Technology in the officeTechnology in the office
Technology in the officecddirks
 
Health Plan Presentation 4.21.15
Health Plan Presentation 4.21.15Health Plan Presentation 4.21.15
Health Plan Presentation 4.21.15Doug Fellers
 
Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17
Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17
Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17Tahoe eLab
 
The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017
The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017
The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017Tahoe eLab
 
AMP-Based Variant Classification with VSClinical
AMP-Based Variant Classification with VSClinicalAMP-Based Variant Classification with VSClinical
AMP-Based Variant Classification with VSClinicalGolden Helix
 
Improving the prevention, recognition and management of AKI: the ‘Think Kidne...
Improving the prevention, recognition and management of AKI: the ‘Think Kidne...Improving the prevention, recognition and management of AKI: the ‘Think Kidne...
Improving the prevention, recognition and management of AKI: the ‘Think Kidne...Renal Association
 
World stem cells & regenerative medicine congress, london, may 22, 2013
World stem cells & regenerative medicine congress, london, may 22, 2013World stem cells & regenerative medicine congress, london, may 22, 2013
World stem cells & regenerative medicine congress, london, may 22, 2013Advanced Cell Technology, Inc.
 
Act corporate-presentation---may-2013---wscrm---print-version
Act corporate-presentation---may-2013---wscrm---print-versionAct corporate-presentation---may-2013---wscrm---print-version
Act corporate-presentation---may-2013---wscrm---print-versionJohn Redaelli
 
Module 6.2 Hematological Tests
Module 6.2 Hematological TestsModule 6.2 Hematological Tests
Module 6.2 Hematological TestsHannah Nelson
 
Measurement for Improvement - Management of Acute Kidney Injury in primary c...
Measurement for Improvement - Management of Acute Kidney Injury in primary c...Measurement for Improvement - Management of Acute Kidney Injury in primary c...
Measurement for Improvement - Management of Acute Kidney Injury in primary c...Renal Association
 
03 manajemen risiko klinik (mrk)
03 manajemen risiko klinik (mrk)03 manajemen risiko klinik (mrk)
03 manajemen risiko klinik (mrk)Joni Iswanto
 
Efficient Delivery of Healthcare Services to Patients -Jack Nagel, Alpha Heal...
Efficient Delivery of Healthcare Services to Patients -Jack Nagel, Alpha Heal...Efficient Delivery of Healthcare Services to Patients -Jack Nagel, Alpha Heal...
Efficient Delivery of Healthcare Services to Patients -Jack Nagel, Alpha Heal...IMS Marketing
 
April White (linkedin)
April White (linkedin)April White (linkedin)
April White (linkedin)April White
 
April White (linkedin)
April White (linkedin)April White (linkedin)
April White (linkedin)April White
 
Part 2 MHFS, how to build MDHFP
Part 2 MHFS, how to build MDHFPPart 2 MHFS, how to build MDHFP
Part 2 MHFS, how to build MDHFPasadsoomro1960
 
PVPI _ A Cost Effective Programme For Patients
PVPI _ A Cost Effective Programme For Patients PVPI _ A Cost Effective Programme For Patients
PVPI _ A Cost Effective Programme For Patients Nani Karnam Vinayakam
 
7DS Board Assurance Framework: Planning or June 2019 submission
7DS Board Assurance Framework: Planning or June 2019 submission7DS Board Assurance Framework: Planning or June 2019 submission
7DS Board Assurance Framework: Planning or June 2019 submissionNHS England
 

Similar to Nursing aspects-of-ecp (20)

Technology in the office
Technology in the officeTechnology in the office
Technology in the office
 
Health Plan Presentation 4.21.15
Health Plan Presentation 4.21.15Health Plan Presentation 4.21.15
Health Plan Presentation 4.21.15
 
Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17
Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17
Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17
 
The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017
The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017
The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017
 
AMP-Based Variant Classification with VSClinical
AMP-Based Variant Classification with VSClinicalAMP-Based Variant Classification with VSClinical
AMP-Based Variant Classification with VSClinical
 
Improving the prevention, recognition and management of AKI: the ‘Think Kidne...
Improving the prevention, recognition and management of AKI: the ‘Think Kidne...Improving the prevention, recognition and management of AKI: the ‘Think Kidne...
Improving the prevention, recognition and management of AKI: the ‘Think Kidne...
 
Act corp-pres-may13
Act corp-pres-may13Act corp-pres-may13
Act corp-pres-may13
 
World stem cells & regenerative medicine congress, london, may 22, 2013
World stem cells & regenerative medicine congress, london, may 22, 2013World stem cells & regenerative medicine congress, london, may 22, 2013
World stem cells & regenerative medicine congress, london, may 22, 2013
 
Act corporate-presentation---may-2013---wscrm---print-version
Act corporate-presentation---may-2013---wscrm---print-versionAct corporate-presentation---may-2013---wscrm---print-version
Act corporate-presentation---may-2013---wscrm---print-version
 
Module 6.2 Hematological Tests
Module 6.2 Hematological TestsModule 6.2 Hematological Tests
Module 6.2 Hematological Tests
 
Measurement for Improvement - Management of Acute Kidney Injury in primary c...
Measurement for Improvement - Management of Acute Kidney Injury in primary c...Measurement for Improvement - Management of Acute Kidney Injury in primary c...
Measurement for Improvement - Management of Acute Kidney Injury in primary c...
 
03 manajemen risiko klinik (mrk)
03 manajemen risiko klinik (mrk)03 manajemen risiko klinik (mrk)
03 manajemen risiko klinik (mrk)
 
Efficient Delivery of Healthcare Services to Patients -Jack Nagel, Alpha Heal...
Efficient Delivery of Healthcare Services to Patients -Jack Nagel, Alpha Heal...Efficient Delivery of Healthcare Services to Patients -Jack Nagel, Alpha Heal...
Efficient Delivery of Healthcare Services to Patients -Jack Nagel, Alpha Heal...
 
April White (linkedin)
April White (linkedin)April White (linkedin)
April White (linkedin)
 
April White (linkedin)
April White (linkedin)April White (linkedin)
April White (linkedin)
 
Part 2 MHFS, how to build MDHFP
Part 2 MHFS, how to build MDHFPPart 2 MHFS, how to build MDHFP
Part 2 MHFS, how to build MDHFP
 
PVPI _ A Cost Effective Programme For Patients
PVPI _ A Cost Effective Programme For Patients PVPI _ A Cost Effective Programme For Patients
PVPI _ A Cost Effective Programme For Patients
 
7DS Board Assurance Framework: Planning or June 2019 submission
7DS Board Assurance Framework: Planning or June 2019 submission7DS Board Assurance Framework: Planning or June 2019 submission
7DS Board Assurance Framework: Planning or June 2019 submission
 
Cancer Cure
Cancer CureCancer Cure
Cancer Cure
 
Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering...
Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering...Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering...
Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering...
 

Nursing aspects-of-ecp

  • 1. The Royal Marsden 1 Nursing and Service Aspects of Extracorporeal Photopheresis ( ECP) Janet Baker (Sister-Haem-Onc Daycare/Outpts/Apheresis) Royal Marsden NHS Foundation Trust EBMT NAP UK 5/10/2012
  • 2. The Royal Marsden 2 Background  Opportunity to deliver ECP at RMH  Commercially sponsored clinical trial: ECP for 1st line Chronic GvHD  Provision of CellEx™ Photopheresis system  Charity funded programme for Acute GvHD  Development of an ECP service
  • 3. The Royal Marsden 3 Discussion Points  Clinical Governance Issues  Management, Organisation, and Personnel  Training and Supervision  Premises-Space-Storage  Key Documentation  Quality Assurance/ Standards  Patient Management
  • 4. The Royal Marsden 4 Clinical Governance Issues  Service Objectives / Outcome  Service Agreements/ Maintenance  New Equipment User Group  Drug and Therapeutics Committee-Approval for 8- Methoxypsoralen (Uvadex™)  Risk Assessment  Incident Reporting System  Procurement  Finance Reporting- updates to Charity Fund
  • 5. The Royal Marsden 5 Management, Organisation, and Personnel  ? Extension / Integration of Apheresis service  Inpatient / outpatient service  Designated leads/ Keyworkers: Nursing and Medical  Accountability / Responsibility  Skill mix / Experience: Apheresis + Transplant  Resources: Nursing Staff and Time  Institutional / Department support
  • 6. The Royal Marsden 6 Training Requirements  Technical Competency Certificate from Company Trainer – ‘water treatment’ and patient treatments  Theoretical component- workbook  Arranged observational visit to Nottingham -ECP  Strasbourg- Company HQ, and clinical observational visit  On- the – job training / learning….ongoing  Instruction Manual
  • 7. The Royal Marsden 7 Premises – Space - Storage  CellEx™  Location of procedure – Inpt/ Outpt/ Apheresis  Therapeutic environment  Service is portable  Storage of kits
  • 8. The Royal Marsden 8 Key Documentation  Standard Operating Procedure ( SOP) for ECP  Patient Consent Form  Patient Information Leaflet  Photopheresis Procedure record  Prescription/ Proforma -Uvadex™ / Heparin  GvHD monitoring/ assessment form  FACT-BMT Quality of Life questionnaire  Reporting forms for System failures/Incidents  Maintenance and Cleaning records
  • 9. The Royal Marsden 9 Quality Assurance / Standards  SOP policy for ECP and associated policies  JACIE accredited centre  JACIE 5th edn standards B7.2 acknowledge: - “Inspectors are encountering ECP processes during inspection-if part of therapy for GvHD- must comply with JACIE standards-performed according to policies for safe administration of ECP”  UK Photopheresis Society (UKPS) advocates ECP accreditation in UK / Europe by external assessment
  • 10. The Royal Marsden 10 Patient Management  Patient selection / Eligibility for treatment – SOP ‘ to ECP or not to ECP?’  Further consensus guidelines for acute GvHD needed  Scheduling –treatment efficacy -Acute –twice weekly-8 wks - Chronic- per trial / 2x week every 2 weeks - logistics and practicalities  Clinical pre-assessment criteria-blood values (Fbc, Coag, U&es, Lfts, lipids) / Weight  Baseline GvHD assessment and I/S medication review
  • 11. The Royal Marsden 11 Patient Consent / Information  Commitment / Compliance  Repeat hospital visits  Inpt/ Outpt  Realistic aims and timeframes- not ‘quick fix’  Support / Reassurance  Low fat diet- ( lipids)  UVA protection skin / eyes - dark glasses  Contraception – (Uvadex ™)  Good oral hydration  Acute/ Chronic GvHD pts… different needs
  • 12. The Royal Marsden 12 Side –effect profile  Fatigue  Hypotension / dizziness/ syncope - ECV  Increased sensitivity to sunlight- skin / eyes  Pain, anxiety, bruising – peripheral cannulation  Infection- central access lines  Bleeding/ bruising – anticoagulation  Metallic taste in mouth , ‘sparkly’ sensation in eyes during re-infusion
  • 13. The Royal Marsden 13 Venous access - vein assessment  Peripheral Access– Kimal needle size 16/17 - 17/18 g cannula Return - 18/ 20 g cannula  Central Line –Double lumen - LTS line(long term silicone,tunnelled) - 12 French ( 5.5 mm per lumen) - > 3 French per lumen - provide flow rates > 15 ml/ min  CellEx™ - Single or Double lumen procedure
  • 14. The Royal Marsden 14 Transfusion Requirements pre ECP  Institutional Parameters  Hct > 27 %  Platelets > 25,ooo  Blood results < 48 hours pre procedure
  • 15. The Royal Marsden 15 Anticoagualtion  System licensed for Heparin not Citrate  ? Anticoagulant not anti-platelet clumping activity  10,ooo units Heparin in 500 mls / AC ratio 10:1  Adjust for high/ low platelet counts  Watch for Platelet Clumping  Assess for bleeding, bruising - haematuria  Patient anti-coag history- INR
  • 16. The Royal Marsden 16 Technical problems  CellEx™ Alarms  Problem solving  Technical support - Hotline / UK trainer  Kits - Reimbursement if problems  Smart Cards- send for analysis  Reporting / Documenting System and kit problems
  • 17. The Royal Marsden 17 Assessment, Monitoring, Evaluation  Efficacy v toxicity of treatment - ECP good safety profile  GvHD assessments - who should complete these?  Record Clinical Outcomes - ? National ECP database  Quality of Life information  Financial Outcomes - Commissioners / Reimbursement and future funding  Evidence -based and cost- effective service
  • 18. The Royal Marsden 18 Our experience so far…….  3 AGvHD patients treated- 1 in treatment  CGvHD Trial - 1 pt enrolled- not randomised to ECP  ? Future after funding/ trial complete  Challenging / time-consuming  Great opportunity for us and our patients  Collaboration and networking with other ECP centres
  • 19. The Royal Marsden 19 Acknowledgement / Thanks  Regina De Jesus - Joint ECP Key- worker - Sister, Transplant Unit, RMH  Nurses on Bud Flanagan Ambulatory Care ( BFAC)  ECP experts, esp - Emma Luke at Nottingham - Tracy Maher and Maggie Foster at Rotherham
  • 20. The Royal Marsden 20 Thank You for listening. – Questions?
  • 21. The Royal Marsden 21 References  FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing, and Administration. 5th edition. JACIE